Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 5:00 p.m. GMT (12:00 p.m. EST).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 5:00 p.m. GMT (12:00 p.m. EST).
The live event and replay will be available via the company’s Events page on its investor website: https://investors.lexpharma.com/.
Details
News Market Reaction – LXRX
On Nov 11, the day this news came out, LXRX closed 9.86% above the previous close.
Data tracked by StockTitan Argus for the Nov 11 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST).
The live events and replays of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.